Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models

Bibliography

• Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2002;89:237–249.
   Web of Science ®Google Scholar
• Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115–124.
   PubMed Web of Science ®Google Scholar
• Vekris A, Meynard D, Haaz M, et al. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 2004;64:356–362.
   PubMed Web of Science ®Google Scholar
• Chen JF, Ding HM, Wang JX, et al. Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. Biomaterials. 2004;25:723–727.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp J, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2005;16:175–183.
   Web of Science ®Google Scholar
• Allen T, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068:133–141.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
   PubMed Web of Science ®Google Scholar
• Meerum TJ, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol. 2002;49:201–210.
   PubMed Web of Science ®Google Scholar
• Peeters PA, Storm G, Crommelin DJ. Immunoliposomes in vivo: state of the art. Adv Drug Deliv Rev. 1988;1:249–266.
   Google Scholar
• Gao J, Sun J, Li H, et al. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials. 2010;31:2655–2664.
   PubMed Web of Science ®Google Scholar
• Park J, Kirpotin D, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001;74:95–113.
   PubMed Web of Science ®Google Scholar
• Moasser M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–6487.
   PubMed Web of Science ®Google Scholar
• Löfblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670–2680.
   PubMed Web of Science ®Google Scholar
• Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel. 2007;10:167–175.
   PubMedGoogle Scholar
• Badescu G, Bryant P, Swierkosz J, et al. A new reagent for stable thiol-specific conjugation. Bioconjug Chem. 2014;25:460–469.
   PubMed Web of Science ®Google Scholar
• Alavizadeh SH, Badiee A, Golmohammadzadeh S, et al. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. Int J Pharm. 2014;473:326–333.
   PubMed Web of Science ®Google Scholar
• Zisman N, Dos Santos N, Johnstone S, et al. Optimizing liposomal cisplatin efficacy through membrane composition manipulations. Chemother Res Pract. 2011;2011:213848.
   PubMedGoogle Scholar
• Bartlett G. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–468.
   PubMed Web of Science ®Google Scholar
• Ishida T, Iden D, Allen T. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999;460:129–133.
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Hong K, Zheng W, et al. Methods of forming protein-linked lipidic microparticles, and compositions thereof. US 6,210,707 B1. 2001 Apr 3.
   Google Scholar
• Jalali S, Sankian M, Tavakkol-Afshari J, et al. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine. 2012;8:692–701.
   PubMed Web of Science ®Google Scholar
• Krieger M, Eckstein N, Schneider V, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm. 2010;389:10–17.
   PubMed Web of Science ®Google Scholar
• Meerum TJ, Tibben M, Welbank H, et al. Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. Anal Bioanal Chem. 2000;366:298–302.
   Web of Science ®Google Scholar
• Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12:1606–1614.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu W, Xia Y, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 2011;32:3459–3470.
   PubMed Web of Science ®Google Scholar
• Lasic DD, Needham D. The” stealth” liposome: a prototypical biomaterial. Chem Rev. 1995;95:2601–2628.
   Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink W, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175–187.
   PubMed Web of Science ®Google Scholar
• Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63:161–169.
   PubMed Web of Science ®Google Scholar
• Harrington K, Lewanski C, Northcote A, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol. 2001;12:493–496.
   PubMed Web of Science ®Google Scholar
• Newman M, Colbern G, Working P, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43:1.
   PubMed Web of Science ®Google Scholar
• Zamboni W, Gervais A, Egorin M, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004;53:329.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil® the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117.
   PubMed Web of Science ®Google Scholar
• Horowitz A, Barenholz Y, Gabizon A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta. 1992;1109:203–209.
   PubMed Web of Science ®Google Scholar
• Soloman R, Gabizon A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma Leuk. 2008;8:21–32.
   Web of Science ®Google Scholar
• Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res. 2008;18:293–307.
   PubMed Web of Science ®Google Scholar
• Amin M, Badiee A, Jaafari M. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm. 2013;458:324–333.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Tzemach D, Gorin J, et al. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol. 2010;66:43–52.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Ishida T, Okada Y, et al. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007;329:94–102.
   PubMed Web of Science ®Google Scholar
• Molavi O, Xiong X, Douglas D, et al. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials. 2013;34:8718–8725.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2006;9:E128–E147.
   Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:S3–8.
   PubMed Web of Science ®Google Scholar
• Smith B, Lyakhov I, Loomis K, et al. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+affisomes). J Control Release. 2011;153:187–194.
   PubMed Web of Science ®Google Scholar
• Park J, Hong K, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A. 1995;92:1327–1331.
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park J, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997;36:66–75.
   PubMed Web of Science ®Google Scholar
• Maruyama K. PEG-immunoliposome. Biosci Rep. 2002;22:251–266.
   PubMed Web of Science ®Google Scholar
• Uster P, Allen T, Daniel B, et al. Insertion of poly (ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 1996;386:243–246.
   PubMed Web of Science ®Google Scholar
• Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339–4348.
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–79.
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen T. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res. 2003;42:439–462.
   PubMed Web of Science ®Google Scholar
• Huang S, Lee K, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992;52:5135–5143.
   PubMed Web of Science ®Google Scholar
• Alexis F, Basto P, Levy‐Nissenbaum E, et al. HER2argeted nanoparticle–affibody bioconjugates for cancer therapy. ChemMedChem. 2008;3:1839–1843.
   PubMed Web of Science ®Google Scholar
• Tan W, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials. 2007;28:1565.
   PubMed Web of Science ®Google Scholar
• Nellis D, Ekstrom D, Kirpotin D, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2004;21:205–220.
   Web of Science ®Google Scholar
• Park J, Hong K, Kirpotin D, et al. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997;118:153.
   PubMed Web of Science ®Google Scholar
• Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648.
   PubMed Web of Science ®Google Scholar
• Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Pietras R, Fendly B, Chazin V, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829–1838.
   PubMed Web of Science ®Google Scholar
• Hare J, Moase E, Allen T. Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer. J Drug Targeting. 2013;21:87–96.
   PubMed Web of Science ®Google Scholar
• Lozano N, Al-Ahmady Z, Beziere N, et al. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent. Int J Pharm. 2015;482:2–10.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Vehmeijer L, Kok R, et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 2013;65:1284–1298.
   PubMed Web of Science ®Google Scholar